Q-omics provides the consensus-scored FAM20A profile across patient tissues and cancer cell-line models. FAM20A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM20A is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FAM20A RNA expression shows 24,594 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where FAM20A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM20A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM20A survival associations across molecular data types. FAM20A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM20A RNA expression–survival associations across cancer types. High FAM20A expression shows unfavorable associations in KIRC, UVM, UCEC and LGG, but favorable associations in SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM20A RNA expression.
This table summarizes FAM20A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM20A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM20A shows lower tumor expression in KICH, BRCA, KIRC, LUSC and KIRP and higher tumor expression in THCA. The KICH box plot shows higher FAM20A RNA expression in normal versus tumor tissue (log2 FC = −2.880, t-test p < 0.001).
This table shows molecular features associated with FAM20A in patient tissues and cancer cell lines. In patient samples, FAM20A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM20A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
